Global Biosimilar Monoclonal Antibodies market will reach 15.2 Billion US$ by the end of 2025

Publisher: QYResearch
Published Date: 2019/8/15

Market analysts say there could be opportunities opening up in the global biosimilar monoclonal antibodies market as monopoly drugs or generic biologics reach their patent expiry dates. There are also various other types of drugs that have already been expired. Some of the traditional patented drugs sold in the market may not be affordable for patients. Thus, the availability of cost-effective alternatives that reduce the cost burden of patients could be another factor pushing the growth of the global market.

The demand for biosimilar drugs is expected to increase on the back of the need for low-cost medications, especially in developing countries. The global biosimilar monoclonal antibodies market is predicted to gain support from the growing incidence of different cancer types, oncological disorders, and other chronic diseases. Heavy investment of pharmaceutical companies in the research and development of biosimilar drugs is foreseen to augment the demand in the global market.

However, tight government regulations and expensive manufacturing cost are foretold to pose challenges to manufacturers of biosimilar monoclonal antibodies.

The global biosimilar monoclonal antibodies market is anticipated to expand at an exponential CAGR of 27.7% during the forecast period 2019-2025. The global market valuation is projected to reach US$15.2 Bn by 2025, jumping from US$2.7 Bn obtained in 2018.

Click to view the full report:
https://www.qyresearch.com/index/detail/1076672/global-biosimilar-monoclonal-antibodies-market
This article was first released by QYResearch, if reproduced, please indicate the source.
Telephone number:020-22093278
Contact:press@qyresearch.com
When contacting, please refer to QYR company's Mia introduction.